Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Fast Track Articles
  5. Fast Track Article
image of An Updated Review on Dysregulated lncRNAs and their Contribution to the Various Molecular Types of Lung Carcinoma

Abstract

Lung cancer is correlated with a high death rate, with approximately 1.8 million mortality cases reported worldwide in 2022. Despite development in the control of lung cancer, most cases are detected at higher stages with short survival rates. This reveals a need to recognize novel techniques to treat malignancy and decrease the burden of lung cancer. Long noncoding RNAs (lncRNAs) manage vital cellular and biochemical functions. lncRNAs play crucial roles in transcriptional and translational processes and signaling cascades. Recently, lncRNAs have been reported to be associated with malignancy where their expression is deregulated, leading to abnormal cellular activities and signaling pathways. In various malignancies, including lung cancer, lncRNA deregulation disrupts normal cellular function, promoting tumorigenesis and influencing patient outcomes and treatment responses. Studies have shown that lncRNAs can act as both oncogenes and tumor suppressors, depending on the lung cancer subtype, specifically in Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). This dual role of lncRNAs as critical biomarkers might provide insights into lung cancer development and progression. lncRNAs have been discussed as key biomarkers in lung cancer. A comprehensive understanding of the biological activities of lncRNAs in NSCLC and SCLC may improve prognosis, diagnosis, and therapeutic methods. Researchers are increasingly interested in lncRNAs as potential diagnostic biomarkers and therapeutic targets in cancer treatment. As researchers continue to explore lncRNAs, their pivotal roles in lung cancer become increasingly evident. This review highlights the function of lncRNAs in lung carcinogenesis and discusses their molecular mechanisms of function.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206336608241104065557
2025-01-01
2025-01-18

  • From This Site

    /content/journals/acamc/10.2174/0118715206336608241104065557
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Zappa C. Mousa S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016 5 3 288 300 10.21037/tlcr.2016.06.07
    [Google Scholar]
  2. Denisenko T.V. Budkevich I.N. Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018 9 2 117 10.1038/s41419‑017‑0063‑y
    [Google Scholar]
  3. Souza V.G.P. de Araújo R.P. Santesso M.R. Seneda A.L. Minutentag I.W. Felix T.F. Hamamoto Filho P.T. Pewarchuk M.E. Brockley L.J. Marchi F.A. Lam W.L. Drigo S.A. Reis P.P. Advances in the molecular landscape of lung cancer brain metastasis. Cancers (Basel) 2023 15 3 722 10.3390/cancers15030722
    [Google Scholar]
  4. Mezentsev A. Durymanov M. Makarov V.A. A comprehensive review of protein biomarkers for invasive lung cancer. Curr. Oncol. 2024 31 9 4818 4854 10.3390/curroncol31090360
    [Google Scholar]
  5. Arunkumar G. LncRNAs: The good, the bad, and the unknown. Biochem. Cell Biol. 2024 102 1 9 27 10.1139/bcb‑2023‑0155
    [Google Scholar]
  6. Hu Q. Ma H. Chen H. Zhang Z. Xue Q. LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside. Cell Death Discov. 2022 8 1 359 10.1038/s41420‑022‑01157‑4
    [Google Scholar]
  7. Dastmalchi N. Safaralizadeh R. Latifi-Navid S. Banan Khojasteh S.M. Mahmud Hussen B. Teimourian S. An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer. Expert Rev. Mol. Diagn. 2021 21 10 1025 1036 10.1080/14737159.2021.1962707
    [Google Scholar]
  8. Dastmalchi N. Safaralizadeh R. Banan Khojasteh S.M. The correlation between microRNAs and Helicobacter pylori in gastric cancer. Pathog. Dis. 2019 77 4 ftz039 10.1093/femspd/ftz039
    [Google Scholar]
  9. Dastmalchi N. Safaralizadeh R. Nargesi M.M. LncRNAs: Potential novel prognostic and diagnostic biomarkers in colorectal cancer. Curr. Med. Chem. 2020 27 30 5067 5077 10.2174/0929867326666190227230024
    [Google Scholar]
  10. Mohammadrezakhani H. Baradaran B. Shanehbandi D. Asadi M. Hashemzadeh S. Hajiasgharzadeh K. Safaralizadeh R. Overexpression and clinicopathological correlation of long noncoding RNA TMPO-AS1 in colorectal cancer patients. J. Gastrointest. Cancer 2020 51 3 952 956 10.1007/s12029‑019‑00333‑7
    [Google Scholar]
  11. Ghodrati R. Safaralizadeh R. Dastmalchi N. Hosseinpourfeizi M. Asadi M. Shirmohammadi M. Baradaran B. Overexpression of lncRNA DLEU1 in gastric cancer tissues compared to adjacent non-tumor tissues. J. Gastrointest. Cancer 2022 53 4 990 994 10.1007/s12029‑021‑00733‑8
    [Google Scholar]
  12. Gencel-Augusto J. Wu W. Bivona T.G. long non-coding RNAs as emerging targets in lung cancer. Cancers (Basel) 2023 15 12 3135 10.3390/cancers15123135
    [Google Scholar]
  13. Lu T. Wang Y. Chen D. Liu J. Jiao W. Potential clinical application of lncRNAs in non-small cell lung cancer. OncoTargets Ther. 2018 11 8045 8052 10.2147/OTT.S178431
    [Google Scholar]
  14. Chen X. Zhou F. Ren W. Guo J. Huang X. Pu J. Niu X. Jiang X. LncRNA-AC02278.4 Is a novel prognostic biomarker that promotes tumor growth and metastasis in lung Adenocarcinoma. Front. Oncol. 2022 12 860961 10.3389/fonc.2022.860961
    [Google Scholar]
  15. Chen C. Liu W.R. Zhang B. Zhang L.M. Li C.G. Liu C. Zhang H. Huo Y-S. Ma Y-C. Tian P-F. Qi Q. Li J-J. Tang Z. Zhang Z-F. Giaccone G. Yue D-S. Wang C-L. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. Cancer Lett. 2020 486 58 70 10.1016/j.canlet.2020.05.009
    [Google Scholar]
  16. Wang M. Fu Y. Zhong C. Gacche R.N. Wu P. Long non-coding RNA and evolving drug resistance in lung cancer. Heliyon 2023 9 12 e22591 10.1016/j.heliyon.2023.e22591
    [Google Scholar]
  17. Liu D. Lu X. Huang W. Zhuang W. Long non-coding RNAs in non-small cell lung cancer: Implications for EGFR-TKI resistance. Front. Genet. 2023 14 1222059 10.3389/fgene.2023.1222059
    [Google Scholar]
  18. Guo X. Xia J. Deng K. Long non-coding RNAs: Emerging players in gastric cancer. Tumour Biol. 2014 35 11 10591 10600 10.1007/s13277‑014‑2548‑y
    [Google Scholar]
  19. Da C. Gong C.Y. Nan W. Zhou K.S. Wu Z-L. Zhang H-H. The role of long non-coding RNA MIAT in cancers. Biomed. Pharmacother. 2020 129 110359 10.1016/j.biopha.2020.110359
    [Google Scholar]
  20. Lei T. Lv Z.Y. Fu J.F. Wang Z. Fan Z. Wang Y. LncRNA NBAT-1 is down-regulated in lung cancer and influences cell proliferation, apoptosis and cell cycle. Eur. Rev. Med. Pharmacol. Sci. 2018 22 7 1958 1962
    [Google Scholar]
  21. Chen T. Gao F. Yang T. Li H. Li Y. Ren H. Chen M. LncRNA HOTAIRM1 inhibits the proliferation and invasion of lung adenocarcinoma cells via the miR-498/WWOX axis. Cancer Manag. Res. 2020 12 4379 4390 10.2147/CMAR.S244573
    [Google Scholar]
  22. Kadian L.K. Verma D. Lohani N. Yadav R. Ranga S. Gulshan G. Pal S. Kumari K. Chauhan S.S. Long non-coding RNAs in cancer: Multifaceted roles and potential targets for immunotherapy. Mol. Cell. Biochem. 2024 10.1007/s11010‑024‑04933‑1
    [Google Scholar]
  23. Wang R. Xu Y. Tong L. Zhang X. Zhang S. Recent progress of exosomal lncRNA/circRNA–miRNA–mRNA axis in lung cancer: Implication for clinical application. Front. Mol. Biosci. 2024 11 1417306 10.3389/fmolb.2024.1417306
    [Google Scholar]
  24. Park S.M. Choi E.Y. Bae D.H. Sohn H.A. Kim S.Y. Kim Y.J. The LncRNA EPEL promotes lung cancer cell proliferation through E2F target activation. Cell. Physiol. Biochem. 2018 45 3 1270 1283 10.1159/000487460
    [Google Scholar]
  25. Ma J. Cao K. Ling X. Zhang P. Zhu J. LncRNA HAR1A suppresses the development of non-small cell lung cancer by inactivating the STAT3 pathway. Cancers (Basel) 2022 14 12 2845 10.3390/cancers14122845
    [Google Scholar]
  26. Wu C. Yang J. Li R. Lin X. Wu J. Wu J. LncRNA WT1-AS/miR-494-3p regulates cell proliferation, apoptosis, migration and invasion via PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer. OncoTargets Ther. 2021 14 891 904 10.2147/OTT.S278233
    [Google Scholar]
  27. Liu M. Liu C. Li X. Li S. RP11-79H23.3 Inhibits the proliferation and metastasis of non-small-cell lung cancer through promoting miR-29c. Biochem. Genet. 2023 61 2 506 520 10.1007/s10528‑022‑10263‑y
    [Google Scholar]
  28. Lai X.N. Li J. Tang L.B. Chen W.T. Zhang L. Xiong L.X. MiRNAs and LncRNAs: Dual roles in TGF-β signaling-regulated metastasis in lung cancer. Int. J. Mol. Sci. 2020 21 4 1193 10.3390/ijms21041193
    [Google Scholar]
  29. Li X. Wu Y. Jin Y. Exosomal LncRNAs and CircRNAs in lung cancer: Emerging regulators and potential therapeutic targets. Noncoding RNA Res. 2024 9 4 1069 1079 10.1016/j.ncrna.2024.06.010
    [Google Scholar]
  30. Cheng Z. Lu C. Wang H. Wang N. Cui S. Yu C. Wang C. Zuo Q. Wang S. Lv Y. Yao M. Jiang L. Qin W. Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression. Cancer Lett. 2022 531 1 13 10.1016/j.canlet.2022.01.031
    [Google Scholar]
  31. Gao J. Pan T. Wang H. Wang S. Chai J. Jin C. LncRNA FAM138B inhibits the progression of non-small cell lung cancer through miR-105-5p. Cell Cycle 2023 22 7 808 817 10.1080/15384101.2022.2154556
    [Google Scholar]
  32. Miliotis C. Slack F.J. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. Cancer Lett. 2021 518 115 126 10.1016/j.canlet.2021.05.037
    [Google Scholar]
  33. Sun X. Qiu X. LncRNA TPTEP1 inhibited the proliferation and metastasis of non-small cell lung cancer cells by targeting miR-761/LATS2 axis. Am. J. Transl. Res. 2021 13 8 8653 8669
    [Google Scholar]
  34. Pan H. Peng J. Qiao X. Gao H. Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis. Open Med. (Wars.) 2023 18 1 20230666 10.1515/med‑2023‑0666
    [Google Scholar]
  35. Taghvimi S. Abbaszadeh S. Banan F.B. Fard E.S. Jamali Z. Najafabadi M.A. Savardashtaki A. Movahedpour A. LncRNAs roles in chemoresistance of cancer cells. Curr. Mol. Med. 2022 22 8 691 702 10.2174/1566524021666211027090515
    [Google Scholar]
  36. Guo S. Zhang L. Zhang Y. Wu Z. He D. Li X. Wang Z. Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition. Aging (Albany NY) 2019 11 18 7553 7569 10.18632/aging.102271
    [Google Scholar]
  37. Xia H. Qu X-L. Liu L-Y. Qian D-H. Jing H-Y. LncRNA MEG3 promotes the sensitivity of vincristine by inhibiting autophagy in lung cancer chemotherapy. Eur. Rev. Med. Pharmacol. Sci. 2018 22 4
    [Google Scholar]
  38. Yang T. Li H. Chen T. Ren H. Shi P. Chen M. LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells through directly functioning on miR-197-3p/p120 catenin axis. Mol. Cells 2019 42 3 270 283
    [Google Scholar]
  39. Pan H. Yu T. Sun L. Chai W. Liu X. Yan M. LncRNA FENDRR-mediated tumor suppression and tumor-immune microenvironment changes in non-small cell lung cancer. Transl. Cancer Res. 2020 9 6 3946 3959 10.21037/tcr‑20‑2147
    [Google Scholar]
  40. Wang C. Tao X. Wei J. Effects of LncRNA MEG3 on immunity and autophagy of non-small cell lung carcinoma through IDO signaling pathway. World J. Surg. Oncol. 2021 19 1 244 10.1186/s12957‑021‑02346‑8
    [Google Scholar]
  41. Zhu Y. Shen Y. Chen R. Li H. Wu Y. Zhang F. Huang W. Guo L. Chen Q. Liu H. KCNQ1OT1 lncRNA affects the proliferation, apoptosis, and chemoresistance of small cell lung cancer cells via the JAK2/ STAT3 axis. Ann. Transl. Med. 2021 9 10 891 891 10.21037/atm‑21‑1761
    [Google Scholar]
  42. Yuan X. Shen Q. Ma W. Long noncoding RNA hotair promotes the progression and immune escape in laryngeal squamous cell carcinoma through MicroRNA-30a/GRP78/PD-L1 axis. J Immunol Res. 2022 2022 1 13
    [Google Scholar]
  43. Chen W. Hang Y. Xu W. Wu J. Chen L. Chen J. Mao Y. Song J. Song J. Wang H. BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small‐cell lung cancer. J. Cell. Biochem. 2019 120 2 2540 2546 10.1002/jcb.27548
    [Google Scholar]
  44. Huang Y. Xia L. Tan X. Zhang J. Zeng W. Tan B. Yu X. Fang W. Yang Z. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis. Cell. Mol. Biol. Lett. 2022 27 1 43 10.1186/s11658‑022‑00343‑7
    [Google Scholar]
  45. Xia Y. Wang W.C. Shen W.H. Xu K. Hu Y.Y. Han G.H. Liu Y-B. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454–3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem. Biol. Interact. 2021 349 109652 10.1016/j.cbi.2021.109652
    [Google Scholar]
  46. Shen Q. Zhou H. Zhang M. Wu R. Wang L. Wang Y. Chen J. Super enhancer‐LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. J. Clin. Lab. Anal. 2022 36 6 e24460 10.1002/jcla.24460
    [Google Scholar]
  47. Yan Z. Yang Q. Xue M. Wang S. Hong W. Gao X. YY1-induced lncRNA ZFPM2-AS1 facilitates cell proliferation and invasion in small cell lung cancer via upregulating of TRAF4. Cancer Cell Int. 2020 20 1 108 10.1186/s12935‑020‑1157‑7
    [Google Scholar]
  48. Dao R. Wudu M. Hui L. Jiang J. Xu Y. Ren H. Qiu X. Knockdown of lncRNA MIR503HG suppresses proliferation and promotes apoptosis of non-small cell lung cancer cells by regulating miR-489-3p and miR-625-5p. Pathol. Res. Pract. 2020 216 3 152823 10.1016/j.prp.2020.152823
    [Google Scholar]
  49. Zhang Y. Li Y. Han L. Zhang P. Sun S. SBF2‐AS1: An oncogenic lncRNA in small‐cell lung cancer. J. Cell. Biochem. 2019 120 9 15422 15428 10.1002/jcb.28809
    [Google Scholar]
  50. Luo H. Zhang Y. Qin G. Jiang B. Miao L. LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer. BMC Cancer 2021 21 1 820 10.1186/s12885‑021‑08365‑8
    [Google Scholar]
  51. Wang D. Wu W. Huang W. Wang J. Luo L. Tang D. LncRNA LUADT1 sponges miR-15a-3p to upregulate Twist1 in small cell lung cancer. BMC Pulm. Med. 2019 19 1 246 10.1186/s12890‑019‑0991‑7
    [Google Scholar]
  52. Pan J. Fang S. Tian H. Zhou C. Zhao X. Tian H. He J. Shen W. Meng X. Jin X. Gong Z. lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling. Mol. Cancer 2020 19 1 9 10.1186/s12943‑020‑1133‑9
    [Google Scholar]
  53. Su H. Fan G. Huang J. Qiu X. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death Dis. 2022 13 4 307 10.1038/s41419‑022‑04723‑x
    [Google Scholar]
  54. Li B. Zhu L. Li L. Ma R. lncRNA OXCT1-AS1 promotes metastasis in non-small-cell lung cancer by stabilizing LEF1, in vitro and in vivo. Biomed Res Int. 2021 2021 1 15
    [Google Scholar]
  55. Lu G. Zhang Y. Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p. PLoS One. 2020 15 2 e0229118 10.1371/journal.pone.0229118
    [Google Scholar]
  56. Güçlü E. Eroğlu Güneş C. Kurar E. Vural H. Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy. Med. Oncol. 2021 38 9 113 10.1007/s12032‑021‑01562‑2
    [Google Scholar]
  57. Zeng F. Wang Q. Wang S. Liang S. Huang W. Guo Y. Peng J. Li M. Zhu W. Guo L. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene 2020 39 2 293 307 10.1038/s41388‑019‑0984‑2
    [Google Scholar]
  58. Hua J. Wang X. Ma L. Li J. Cao G. Zhang S. Lin W. CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. Mol. Cancer 2022 21 1 123 10.1186/s12943‑022‑01595‑9
    [Google Scholar]
  59. Chung E.K. Yong S.H. Lee E.H. Kim E.Y. Chang Y.S. Lee S.H. New targeted therapy for non-small cell lung cancer. Tuberc. Respir. Dis. (Seoul) 2023 86 1 1 13 10.4046/trd.2022.0066
    [Google Scholar]
  60. Shah R. Lester J.F. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: A clash of the generations. Clin. Lung Cancer 2020 21 3 e216 e228 10.1016/j.cllc.2019.12.003
    [Google Scholar]
  61. Li Y. Shen Y. Xie M. Wang B. Wang T. Zeng J. Hua H. Yu J. Yang M. LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and EIF2S1. Signal Transduct. Target. Ther. 2022 7 1 30 10.1038/s41392‑021‑00847‑2
    [Google Scholar]
  62. Xu L.M. Yuan Y.J. Yu H. Wang S. Wang P. LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis. J. Transl. Med. 2022 20 1 350 10.1186/s12967‑022‑03516‑2
    [Google Scholar]
  63. Chen Z. Chen Z. Xu S. Zhang Q. LncRNA SOX2-OT/miR-30d-5p/PDK1 regulates PD-L1 checkpoint through the mtor signaling pathway to promote non-small cell lung cancer progression and immune escape. Front. Genet. 2021 12 674856 10.3389/fgene.2021.674856
    [Google Scholar]
  64. Xia R. Geng G. Yu X. Xu Z. Guo J. Liu H. Li N. Li Z. Li Y. Dai X. Luo Q. Jiang J. Mi Y. LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs. J. Immunother. Cancer 2021 9 8 e002746 10.1136/jitc‑2021‑002746
    [Google Scholar]
  65. Du Z. Niu S. Wang J. Wu J. Li S. Yi X. SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis. Autoimmunity 2021 54 4 225 233 10.1080/08916934.2021.1913582
    [Google Scholar]
  66. Li J. Che L. Xu C. Lu D. Xu Y. Liu M. Chai W. XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8 + T cells. J. Recept. Signal Transduct. Res. 2022 42 5 469 478 10.1080/10799893.2021.2019274
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206336608241104065557
Loading
An Updated Review on Dysregulated lncRNAs and their Contribution to the Various Molecular Types of Lung Carcinoma
Bentham Science Publishers ; https://doi.org/10.2174/0118715206336608241104065557
/content/journals/acamc/10.2174/0118715206336608241104065557
/content/journals/acamc/10.2174/0118715206336608241104065557
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Lung cancer ; lncRNAs ; aberrant functions ; molecular mechanism

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test